Trimetrexate
Executive Summary
Memorial-Sloan Kettering Cancer Institute study finding that trimetrexate enhances the efficacy of 5-FU will be presented at the American Society of Clinical Oncology conference in Orlando the week of May 17, U.S. Bioscience's Philip Schein advises. The company has been studying trimetrexate glucuronate, tradenamed Neutrexin, for several indications, including treatment of advanced non-small cell lung cancer, prostate cancer and pancreatic cancers. An NDA is pending for second-line treatment of Pneumocystis carinii pneumonia.